Advyzon Investment Management LLC Buys Shares of 14,100 Emergent Biosolutions Inc. $EBS

Advyzon Investment Management LLC bought a new position in shares of Emergent Biosolutions Inc. (NYSE:EBS) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 14,100 shares of the biopharmaceutical company’s stock, valued at approximately $90,000.

Other institutional investors also recently modified their holdings of the company. Acadian Asset Management LLC raised its position in Emergent Biosolutions by 313.5% in the first quarter. Acadian Asset Management LLC now owns 833,316 shares of the biopharmaceutical company’s stock valued at $4,048,000 after purchasing an additional 631,794 shares during the last quarter. Wolverine Asset Management LLC increased its stake in shares of Emergent Biosolutions by 28.3% in the second quarter. Wolverine Asset Management LLC now owns 174,933 shares of the biopharmaceutical company’s stock valued at $1,116,000 after buying an additional 38,600 shares during the period. Prescott Group Capital Management L.L.C. raised its holdings in Emergent Biosolutions by 198.9% in the 1st quarter. Prescott Group Capital Management L.L.C. now owns 627,671 shares of the biopharmaceutical company’s stock valued at $3,050,000 after buying an additional 417,671 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Emergent Biosolutions by 12.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,090,655 shares of the biopharmaceutical company’s stock worth $5,301,000 after buying an additional 121,583 shares during the period. Finally, New York State Common Retirement Fund grew its holdings in Emergent Biosolutions by 22.4% during the 1st quarter. New York State Common Retirement Fund now owns 375,034 shares of the biopharmaceutical company’s stock worth $1,823,000 after acquiring an additional 68,748 shares during the last quarter. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

EBS has been the subject of several analyst reports. Weiss Ratings raised shares of Emergent Biosolutions from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Emergent Biosolutions in a research report on Wednesday, September 3rd. Zacks Research raised Emergent Biosolutions to a “hold” rating in a report on Friday, October 24th. Finally, Wall Street Zen raised Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a research note on Sunday. One equities research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Emergent Biosolutions currently has an average rating of “Hold” and a consensus target price of $15.00.

Insider Activity

In related news, Director Kathryn C. Zoon sold 7,086 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $8.87, for a total transaction of $62,852.82. Following the transaction, the director directly owned 71,799 shares of the company’s stock, valued at approximately $636,857.13. This represents a 8.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Coleen Glessner sold 30,608 shares of the company’s stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $10.00, for a total value of $306,080.00. Following the transaction, the executive vice president directly owned 144,319 shares in the company, valued at approximately $1,443,190. This trade represents a 17.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.20% of the stock is currently owned by corporate insiders.

Emergent Biosolutions Price Performance

Emergent Biosolutions stock opened at $10.80 on Thursday. The stock has a market capitalization of $566.95 million, a price-to-earnings ratio of 8.30 and a beta of 2.05. Emergent Biosolutions Inc. has a 52-week low of $4.02 and a 52-week high of $13.41. The company has a debt-to-equity ratio of 1.25, a quick ratio of 3.00 and a current ratio of 5.66. The stock’s 50 day moving average price is $9.26 and its two-hundred day moving average price is $7.72.

Emergent Biosolutions (NYSE:EBS) last released its earnings results on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter. The company had revenue of $222.50 million for the quarter. Emergent Biosolutions had a net margin of 9.62% and a return on equity of 21.43%. Emergent Biosolutions has set its FY 2023 guidance at EPS. On average, equities analysts predict that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current year.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.